For outsourcing facilities under section 503B of the FD&C Act: compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved drug product within 90 calendar days from todays announcement, until May 22, 2025
While this multipronged effect is what makes it effective, it also creates multiple avenues where it can seriously impact a patients health
Studies suggest a correlation between using GLP-1 drugs and an increased risk of developing thyroid cancers
Two-thirds (68%) report being considerably concerned about rising costs and 94% believe GLP-1s will increase the cost of healthcare overall
This reduction was driven primarily by fewer nonfatal strokes (39% reduction) and nonfatal heart attacks (26% reduction), establishing semaglutide's role in cardiovascular protection for diabetic patients
Schedule your first glutathione push with IV Elements Ready to enhance your wellness journey with an in-lounge or mobile glutathione push in NJ, NYC, or PA